Integra Lifesciences (NASDAQ:IART) received a $54.00 price objective from investment analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday. The firm currently has a “hold” rating on the life sciences company’s stock. Cantor Fitzgerald’s price target would indicate a potential upside of 18.42% from the stock’s previous close.

Several other equities analysts have also weighed in on IART. BTIG Research restated a “buy” rating and set a $69.00 price target on shares of Integra Lifesciences in a research report on Wednesday, September 12th. Zacks Investment Research lowered shares of Integra Lifesciences from a “hold” rating to a “sell” rating in a research report on Tuesday, September 25th. Oppenheimer restated a “buy” rating on shares of Integra Lifesciences in a research report on Tuesday, October 2nd. Morgan Stanley set a $68.00 price target on shares of Integra Lifesciences and gave the company a “hold” rating in a research report on Thursday, October 11th. Finally, BidaskClub upgraded shares of Integra Lifesciences from a “hold” rating to a “buy” rating in a research report on Friday, October 19th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $62.00.

NASDAQ IART opened at $45.60 on Tuesday. Integra Lifesciences has a 1 year low of $42.14 and a 1 year high of $67.50. The company has a debt-to-equity ratio of 1.04, a current ratio of 3.20 and a quick ratio of 2.08. The firm has a market capitalization of $3.78 billion, a PE ratio of 23.51, a PEG ratio of 1.24 and a beta of 0.93.

Integra Lifesciences (NASDAQ:IART) last posted its quarterly earnings results on Wednesday, October 31st. The life sciences company reported $0.59 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.59. The company had revenue of $365.85 million during the quarter, compared to analyst estimates of $367.89 million. Integra Lifesciences had a net margin of 5.49% and a return on equity of 16.99%. The firm’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.45 earnings per share. Analysts forecast that Integra Lifesciences will post 2.39 earnings per share for the current fiscal year.

In other news, Director Barbara B. Hill purchased 3,705 shares of the stock in a transaction dated Monday, November 5th. The shares were purchased at an average cost of $53.90 per share, with a total value of $199,699.50. Following the completion of the acquisition, the director now owns 63,381 shares in the company, valued at approximately $3,416,235.90. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Richard E. Caruso sold 46,676 shares of the stock in a transaction dated Wednesday, October 17th. The stock was sold at an average price of $63.19, for a total transaction of $2,949,456.44. Following the completion of the sale, the insider now directly owns 134,134 shares in the company, valued at $8,475,927.46. The disclosure for this sale can be found here. 5.10% of the stock is owned by company insiders.

Several institutional investors have recently made changes to their positions in the company. Clearbridge Investments LLC lifted its holdings in shares of Integra Lifesciences by 7.9% in the third quarter. Clearbridge Investments LLC now owns 1,810,641 shares of the life sciences company’s stock worth $119,267,000 after buying an additional 132,805 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of Integra Lifesciences by 3.1% in the third quarter. Legal & General Group Plc now owns 76,875 shares of the life sciences company’s stock worth $5,063,000 after buying an additional 2,333 shares in the last quarter. Nordea Investment Management AB purchased a new stake in shares of Integra Lifesciences in the third quarter worth about $5,089,000. Koshinski Asset Management Inc. purchased a new stake in Integra Lifesciences in the third quarter valued at approximately $201,000. Finally, Sector Gamma AS raised its stake in Integra Lifesciences by 3.7% in the third quarter. Sector Gamma AS now owns 338,733 shares of the life sciences company’s stock valued at $22,312,000 after purchasing an additional 12,074 shares in the last quarter. 85.90% of the stock is currently owned by hedge funds and other institutional investors.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Recommended Story: What is the S&P 500 Index?

Analyst Recommendations for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.